Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from NetraMark Holdings ( (TSE:AIAI) ).
NetraMark Holdings presented groundbreaking studies at the ISCTM conference, showcasing their AI-driven insights in clinical trials for major depressive disorder (MDD) and schizophrenia. Their NetraAI technology significantly improved patient stratification and trial design by enhancing traditional machine learning methods, leading to increased model accuracy and reduced false-positive rates. This advancement positions NetraMark as a leader in leveraging AI for more efficient and effective clinical trials, potentially transforming the way mental health disorders are studied and treated.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in generative AI software, specializing in clinical trial analytics. The company focuses on enhancing machine learning methods to improve patient stratification and trial design in the pharmaceutical industry, particularly for mental health disorders like major depressive disorder and schizophrenia.
YTD Price Performance: 30.71%
Average Trading Volume: 14,639
Technical Sentiment Consensus Rating: Sell
Find detailed analytics on AIAI stock on TipRanks’ Stock Analysis page.